MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.0001, $50,000, $2.57, $300,000, $2.61 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-reporting
TL;DR
MANGOCEUTICALS, INC. dropped an 8-K on Dec 31st covering a big deal and stock sales.
AI Summary
On December 31, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial statements. The company, incorporated in Texas with its principal executive offices in Dallas, operates in the health services sector.
Why It Matters
This filing provides crucial updates on MANGOCEUTICALS, INC.'s recent business activities, including significant agreements and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial pressure or dilution, warranting closer examination.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- December 31, 2024 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Address of Principal Executive Offices
- 8090 (number) — Standard Industrial Classification Code
FAQ
What is the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on December 31, 2024?
The filing indicates a material definitive agreement was entered into, but the specific details are not provided in the provided text excerpt.
What type of equity securities were sold unregistered by MANGOCEUTICALS, INC.?
The filing confirms unregistered sales of equity securities occurred, but the specific type of securities is not detailed in the provided text.
When was MANGOCEUTICALS, INC. incorporated and in which state?
MANGOCEUTICALS, INC. was incorporated in Texas.
What is the primary business address of MANGOCEUTICALS, INC.?
The primary business address is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the SIC code for MANGOCEUTICALS, INC.?
The Standard Industrial Classification code for MANGOCEUTICALS, INC. is 8090, which falls under SERVICES-MISC HEALTH & ALLIED SERVICES, NEC.
Filing Stats: 2,261 words · 9 min read · ~8 pages · Grade level 14.3 · Accepted 2025-01-08 16:30:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $50,000 — pany (" Series B Preferred Stock ") for $50,000, and warrants to purchase 60,000 shares
- $2.57 — nt Shares "), with an exercise price of $2.57 per share; 300 shares of Series B Prefe
- $300,000 — shares of Series B Preferred Stock for $300,000, and Warrants to purchase 396,000 share
- $2.61 — common stock with an exercise price of $2.61 per share; 500 shares of Series B Prefe
- $500,000 — shares of Series B Preferred Stock for $500,000, and Warrants to purchase 660,000 share
- $2.59 — common stock with an exercise price of $2.59 per share; and 50 shares of Series B Pr
- $1,100 — tock, which each have a stated value of $1,100 per share, are described in greater det
- $990,000 — , based on an aggregate stated value of $990,000, a maximum of 440,000 shares of common
- $2.25 — ders thereof, based on a Floor Price of $2.25 per share. If the Warrants issued to
Filing Documents
- form8-k.htm (8-K) — 61KB
- 0001493152-25-001401.txt ( ) — 239KB
- mgrx-20241231.xsd (EX-101.SCH) — 3KB
- mgrx-20241231_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241231_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: January 8, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer